CRVS
Corvus Pharmaceuticals, Inc.
Overview
Corvus Pharmaceuticals develops clinical-stage immunotherapy drug candidates designed to modulate T cell function for treating cancers and immune-mediated diseases.
Corvus Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $1.00B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
15 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2025Earnings2026-03-1218 Q&A exchanges
- Q3 FY2025Earnings2025-11-0415 Q&A exchanges
- Q2 FY2025Earnings2025-08-0811 Q&A exchanges
- Q1 FY2025Earnings2025-05-0823 Q&A exchanges
- Q4 FY2024Earnings2025-03-2516 Q&A exchanges
- Q3 FY2024Earnings2024-11-1324 Q&A exchanges
- Q1 FY2024Earnings2024-05-0620 Q&A exchanges
- Q4 FY2023Earnings2024-03-1917 Q&A exchanges
- Q3 FY2023Earnings2023-11-0712 Q&A exchanges
- Q2 FY2023Earnings2023-08-0813 Q&A exchanges
- Q1 FY2023Earnings2023-05-0820 Q&A exchanges
- Q4 FY2022Earnings2023-03-2822 Q&A exchanges
- Q3 FY2022Earnings2022-11-0615 Q&A exchanges
- Q2 FY2022Earnings2022-08-088 Q&A exchanges
- Q4 FY2021Earnings2022-03-1014 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-0.17—Rev— vs ——EODHD
- Q1 FY20262026-05-10EPS$-0.15 vs $-0.13-11.7%Rev$0 vs ——EODHD
- Q4 FY20252026-03-04EPS$-0.15 vs $-0.13-18.5%Rev$0 vs ——EODHD
- Q3 FY20252025-11-03EPS$-0.12 vs $-0.13+7.7%Rev$0 vs ——EODHD
- Q2 FY20252025-08-06EPS$-0.10 vs $-0.13+23.1%Rev$0 vs ——EODHD
- Q1 FY20252025-06-12EPS$-0.14 vs $-0.12-14.8%Rev$0 vs ——EODHD
- Q4 FY20242025-03-16EPS$-0.14 vs $-0.12-19.1%Rev$88.0K vs ——EODHD
- Q3 FY20242024-11-04EPS$-0.60 vs $-0.11-100.0%Rev$0 vs ——EODHD
- Q2 FY20242024-08-05EPS$-0.04 vs $-0.11+63.6%Rev$0 vs ——EODHD
- Q1 FY20242024-05-05EPS$-0.12 vs $-0.13+7.7%Rev$0 vs ——EODHD
- Q4 FY20232024-03-18EPS$-0.14 vs $-0.12-16.7%Rev$246.0K vs ——EODHD
- Q3 FY20232023-11-06EPS$-0.12 vs $-0.120.0%Rev$0 vs ——EODHD
- Q2 FY20232023-08-07EPS$-0.14 vs $-0.140.0%Rev$0 vs ——EODHD
- Q1 FY20232023-05-07EPS$-0.17 vs $-0.16-6.3%Rev$0 vs ——EODHD
- Q4 FY20222023-03-27EPS$-0.21 vs $-0.23+8.7%Rev$0 vs ——EODHD
- Q3 FY20222022-11-02EPS$-0.32 vs $-0.16-100.0%Rev$0 vs ——EODHD
- Q2 FY20222022-08-07EPS$-0.18 vs $-0.180.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-04EPS$-0.18 vs $-0.15-20.0%Rev$0 vs ——EODHD
- Q4 FY20212022-03-09EPS$-0.20 vs $-0.19-5.3%Rev$0 vs ——EODHD
- Q3 FY20212021-10-31EPS$-0.24 vs $-0.26+7.7%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-0.17 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-0.15 | $-0.13 | -11.7% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-04 | $-0.15 | $-0.13 | -18.5% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $-0.12 | $-0.13 | +7.7% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.10 | $-0.13 | +23.1% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-06-12 | $-0.14 | $-0.12 | -14.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-16 | $-0.14 | $-0.12 | -19.1% | $88.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-04 | $-0.60 | $-0.11 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.04 | $-0.11 | +63.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-05 | $-0.12 | $-0.13 | +7.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-18 | $-0.14 | $-0.12 | -16.7% | $246.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.12 | $-0.12 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.14 | $-0.14 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-0.17 | $-0.16 | -6.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-27 | $-0.21 | $-0.23 | +8.7% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.32 | $-0.16 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $-0.18 | $-0.18 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.18 | $-0.15 | -20.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.20 | $-0.19 | -5.3% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-10-31 | $-0.24 | $-0.26 | +7.7% | $0 | — | — | EODHD |
Source: EODHD. CRVS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks CRVS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $0.63 | $0.55 | +15.4% | -2.4% | -5.0% |
| Q4 FY2025 | $0.40 | $0.35 | +15.4% | -3.6% | -3.4% |
| Q3 FY2025 | $0.70 | $0.56 | +25.3% | -4.3% | -6.7% |
| Q2 FY2025 | $0.50 | $0.45 | +11.0% | +2.5% | +4.0% |
| Q1 FY2024 | $0.69 | $0.55 | +25.7% | +2.0% | -0.4% |
| Q4 FY2024 | $0.62 | $0.52 | +19.3% | +2.9% | +3.0% |
| Q3 FY2024 | $0.70 | $0.57 | +23.0% | +2.3% | +1.3% |
| Q2 FY2024 | $0.71 | $0.57 | +24.3% | +0.1% | 0.0% |
| Q1 FY2023 | $0.67 | $0.54 | +23.7% | +5.7% | +7.2% |
| Q4 FY2023 | $0.70 | $0.58 | +21.0% | +3.2% | +3.5% |
Guidance change history
Sample- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Richard A Miller MdCEO2 yr 6 mo15 callsCurrentSample
CEO since 2023 • 7/8 beats (88%) • last guidance cut Q3 FY2025
- Leiv LeaCFO2 yr 6 mo15 callsCurrentSample
CFO since 2023 • 5/8 beats (63%) • last call held guidance Q2 FY2025
- Jeffrey ArcaraChief Business Officer2 yr 4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2024 • 2/4 beats (50%) • guidance suspended Q1 FY2025
- William Benton JonesSee Remarks2 yr 6 mono recorded callsCurrentSample
OTHER since 2023 • 5/8 beats (63%) • guidance suspended Q2 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CRVS.
$ curl https://api.spokenalpha.com/v1/companies/CRVSFAQ
Frequently asked about CRVS
Where can I find Corvus Pharmaceuticals, Inc.'s (CRVS) earnings call transcripts?
Spoken Alpha indexes CRVS's earnings call transcripts at https://spokenalpha.com/companies/CRVS. Each call links to attributed speakers and parsed analyst Q&A. Corvus Pharmaceuticals, Inc.'s own investor relations page is at https://investor.corvuspharma.com/.
When was Corvus Pharmaceuticals, Inc.'s most recent earnings call?
Corvus Pharmaceuticals, Inc. (CRVS) held its most recent earnings call on 2026-03-12, covering fiscal Q4 2025.
What sector is CRVS in?
Corvus Pharmaceuticals, Inc. (CRVS) operates in the Healthcare sector (Biotechnology industry).